Current Problems in Surgery
Volume 44, Issue 3 , Pages 157-216 , March 2007

Venous Thromboembolism and Cancer

  • David Bergqvist, MD, PhD, FRCS

      Affiliations

    • Professor of Vascular Surgery, Uppsala University Hospital, Department of Surgical Sciences, Uppsala, Sweden
    • ,
  • Joseph A. Caprini, MD, MS, FACS, RVT, FACPh

      Affiliations

    • Department of Surgery, Evanston Northwestern Healthcare, Skokie, IL
    • ,
  • Olena Dotsenko, MD, PhD

      Affiliations

    • Research Fellow, Thrombosis Research Institute, Clinical Trials & Functional Proteomics Lab, London, United Kingdom
    • ,
  • Ajay K. Kakkar, MBBS, BSc, PhD, FRCS

      Affiliations

    • Thrombosis Research Institute, London, United Kingdom
    • ,
  • Rajesh G. Mishra, MD, PhD

      Affiliations

    • Director, Medical Affairs, GlaxoSmithKline, Parsippany, NJ
    • ,
  • Thomas W. Wakefield, MD

      Affiliations

    • University of Michigan Medical Center, Ann Arbor, MI

References 

  1. Shojania KG, Duncan BW, McDonald KM, Wachter RM, Markowitz AJ. Making health care safer: a critical analysis of patient safety practices. Evid Rep Technol Assess (Summ). 2001;43:1–668i-x
  2. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:338-400S
  3. Kakkar VV. Prevention of fatal postoperative pulmonary embolism by low doses of heparin (An international multicentre trial). Lancet. 1975;2:45–51
  4. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin (Overview of results of randomized trials in general, orthopedic, and urologic surgery). N Engl J Med. 1988;318:1162–1173
  5. Anderson FA, Tapson VF, Decousus H, Spyropoulos AC, Turpie AGG, FitzGerald G. IMPROVE, a multinational observational cohort study of practices in prevention of venous thromboembolism in acutely ill medical patients: a comparison with clinical study populations. Blood. 2003;102:3l9a. 5
  6. Caprini JA, Glase C, Martchev D, Oyslender M, Arcelus JI, Maksimovic D. Thrombosis risk factor assessment in surgical patients: compliance with chest consensus guidelines. J Thromb Haemost. 2003;1(Suppl 1):CD125
  7. Friedman R, Gallus A, Cushner F, FitzGerald G, Anderson F GLORY Investigators. Compliance with ACCP Guidelines for Prevention of Venous Thromboembolism: Multinational findings from the global orthopaedic registry (GLORY). Blood. 2003;102:165a
  8. Panju A, Kahn SR, Geerts W, Pineo G, Desjardins L, Turpie A, et al. Utilization of venous thromboprophylaxis in acutely ill medical patients in Canada: results from the Canadian Registry (CURVE). Blood. 2003;102:498a
  9. Stratton MA, Anderson FA, Bussey HI, Caprini J, Comerota A, Haines ST, et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med. 2000;160:334–340
  10. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest. 2001;120:1964–1971
  11. Anderson FA, Audet A-M, St John R. Practices in the prevention of venous thromboembolism. J Thromb Thrombolysis. 1998;5:S7–S11
  12. Bratzler DW, Raskob GE, Murray CK, Bumpus LJ, Piatt DS. Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 1998;158:1909–1912
  13. Huber O, Bournameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge: an underestimated risk. Arch Surg. 1992;127:310–313
  14. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest. 2003;124(6 Suppl):386S–392S
  15. Trowbridge A, Boese CK, Woodruff B, Brindley HH, Lowry WE, Spiro TE. Incidence of posthospitalization proximal deep venous thrombosis after total hip arthroplasty (A pilot study). Clin Orthop. 1994;299:203–208
  16. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ. 1991;302:709–711
  17. Flordal PA, Berggvist D, Burmark US, Ljungstrom KG, Torngren S The Fragmin Multicentre Study Group. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. Eur J Surg. 1996;162:783–789
  18. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, et al. The Thromboprophylaxis Collaborative Group Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet. 1993;341:259–265
  19. Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. Br J Surg. 1997;84:750–759
  20. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients (Results of a meta-analysis). Ann Surg. 1988;208:227–240
  21. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, et al. Low molecular weight heparin versus standard heparin in general and orthopedic surgery: a metaanalysis. Lancet. 1992;340:152–156
  22. Jorgensen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg. 1993;80:689–704
  23. Heit JA, Cohen AT, Anderson FA VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. [abstract] Blood. 2005;106:910
  24. Wheeler HB. Diagnosis of deep vein thrombosis: review of clinical evaluation and impedance plethysmography. Am J Surg. 1985;150:7–13
  25. Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol. 2001;38(2 Suppl 5):12–19
  26. Borow M, Goldson HJ. Postoperative venous thrombosis (Evaluation of five methods of treatment). Am J Surg. 1981;141:245–251
  27. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med. 2004;164:963–968
  28. Oger E EPI-GETBP Study Group. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost. 2000;83:657–660
  29. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809–815
  30. Kröger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006;17:297–303
  31. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. Prophylaxis in Medical Patients with Enoxaparin Study Group A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:793–800
  32. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ PREVENT Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–879
  33. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. ARTEMIS Investigators Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325–329
  34. Kamran SI, Downey D, Ruff RL. Pneumatic sequential compression reduces the risk of deep vein thrombosis in stroke patients. Neurology. 1998;50:1683–1688
  35. Lacut K, Bressollette L, Le Gal G, Etienne E, De Tinteniac A, Renault A, et al. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology. 2005;65:865–869
  36. Kucher N, Koo S, Quiroz , Cooper JM, Paterno MD, Soukonnikov B, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352:969–977
  37. Agency for Healthcare Research and Quality 30 Safe Practices for Better Health Care. Fact Sheet. AHRQ Publication No. 04-P025. Rockville, MD: AHRQ; 2005;March. http://www.ahrq.gov (accessed 28 February 2006).
  38. Donati MB. Cancer and thrombosis. Haemostasis. 1994;24:128–131
  39. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4:465–473
  40. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809–815
  41. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585–593
  42. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 Suppl 1):I17–I21
  43. American Cancer Society. Cancer Facts & Figures. 2006;Available at http://www.cancer.org/docroot/stt/stt_0.asp. accessed 16 August 2006.
  44. Heit JA, O’Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245–1248
  45. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–722
  46. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119:60–68
  47. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy (Risk analysis using Medicare claims data). Medicine (Baltimore). 1999;78:285–291
  48. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87:575–579
  49. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002;87:1076–1077
  50. Clarke-Pearson DL, Jelovsek FR, Creasman WT. Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis. Obstet Gynecol. 1983;61:87–94
  51. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol. 2001;106:6–12
  52. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1–7
  53. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128–1133
  54. Hettiarachchi RJ, Lok J, Prins MH, Buller HR, Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer. 1998;83:180–185
  55. Aderka D, Brown A, Zelikovski A, Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer. 1986;57:1846–1849
  56. Monreal M, Fernandez-Llamazares J, Perandreu J, Urrutia A, Sahuquillo JC, Contel E. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost. 1997;78:1316–1318
  57. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism (Duration of Anticoagulation Trial). N Engl J Med. 2000;342:1953–1958
  58. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338:1169–1173
  59. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326:1240–1245
  60. Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, et al. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients (Findings from the RIETE registry). J Thromb Haemost. 2004;2:1892–1898
  61. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–1850
  62. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?. South Med J. 1980;73:841–843
  63. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000;160:3415–3420
  64. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21:3665–3675
  65. Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlebologie. Prevention and treatment of venous thromboembolism (International Consensus Statement(guidelines according to scientific evidence)). Int Angiol. 2006;25:101–161
  66. Cunningham MS, White B, Hollywood D, O’Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters—a reappraisal of the evidence. Br J Cancer. 2006;94:189–194
  67. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822–2829
  68. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079–2080
  69. Gallus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost. 1997;78:126–132
  70. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (Venous Thromboembolic Disease, version 1). 2006;http://www.nccn.org/professionals/physician_gls/PDF/vte.pdf. Accessed 2006.
  71. Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003;8:381–388
  72. Thodiyil PA, Walsh DC, Kakkar AK. Thromboprophylaxis in the cancer patient. Acta Haematol. 2001;106:73–80
  73. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975–980
  74. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886–889
  75. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153
  76. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and thromboembolism. J Clin Oncol. 2005;23:2123–2129
  77. Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost. 2002;28:45–52
  78. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA. 2001;98:3352–3357
  79. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer. 1994;74:38–45
  80. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130–2135
  81. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2:1266–1271
  82. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate (Final report of VA Cooperative Study #75). Cancer. 1984;53:2046–2052
  83. Trousseau A. Phlegmasia alba dolens (Clinique Medicale de l‘Hotel-Dieu de Paris). 2nd edition. Paris: Bailliere; 1865;
  84. Paspatis GA, Sfyridaki A, Papanikolaou N, Triantafyllou K, Livadiotaki A, Kapsoritakis A, et al. Resistance to activated protein C, factor V Leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiol Haemost Thromb. 2002;32:2–7
  85. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the RISTOS project. Ann Surg. 2006;243:89–95
  86. Nordstrom M, Lindblad B, Anderson H, Bergqvist D, Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ. 1994;308:891–894
  87. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet. 1998;351:1077–1080
  88. Ogren M, Bergqvist D, Wahlander K, Eriksson H, Sternby NH. Trousseau’s syndrome—what is the evidence? (A population-based autopsy study). Thromb Haemost. 2006;95:541–545
  89. Sorensen HT, Baron JA. Hypercoagulability preceding cancer (Venous thromboembolism and subsequent cancer risk). J Thromb Haemost. 2005;3:583–584
  90. Kakkar AK, Haas S, Wolf H, Encke A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost. 2005;94:867–871
  91. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88:913–930
  92. Torngren S, Hagglund G, Molin K, Rieger A. Postoperative deep venous thrombosis and infectious complications (A clinical study of patients undergoing colo-rectal surgery). Scand J Infect Dis. 1980;12:123–127
  93. Torngren S, Rieger A. Prophylaxis of deep venous thrombosis in colorectal surgery. Dis Colon Rectum. 1982;25:563–566
  94. Kum CK, Sim EK, Ngoi SS. Deep vein thrombosis complicating colorectal surgery in the Chinese in Singapore. Ann Acad Med Singapore. 1993;22:895–897
  95. Wille-Jorgensen P, Rasmussen MS, Andersen BR, Borly L. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery. Cochrane Database Syst Rev 2003(4):CD001217.
  96. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997;84:1099–1103
  97. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. [see comments] Br J Surg. 1995;82:496–501
  98. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):188S–203S
  99. Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med. 2003;28:172–197
  100. Bergqvist D, Wu CL, Neal JM. Anticoagulation and neuraxial regional anesthesia: perspectives. Reg Anesth Pain Med. 2003;28:163–166
  101. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001;135:858–869
  102. Scurr JH, Coleridge-Smith PD, Hasty JH. Deep venous thrombosis: a continuing problem. BMJ. 1988;297:28
  103. Rasmussen MS. Does prolonged thromboprophylaxis improve outcome in patients undergoing surgery?. Cancer Treat Rev. 2003;29(Suppl 2):15–17
  104. Falanga A, Piccioli A. Effect of anticoagulant drugs in cancer. Curr Opin Pulm Med. 2005;11:403–407
  105. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? (The influence of heparins on cancer spread). Thromb Haemost. 1999;82:947–952
  106. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944–1948
  107. Bergqvist D. New ways to prevent venous thromboembolism—the pentasaccharide fondaparinux and the thrombin inhibitor ximelagatran—a review. Acta Chir Belg. 2005;105:35–39
  108. Bergqvist D, Agnelli G, Cohen A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F. Prolonged prophylaxis against venous thromboembolism with enoxaparin inpatients undergoing cancer surgery (Long-term survival analysis). Phlebology. 2006;(In press)
  109. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost. 1998;80:10–23
  110. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6:401–410
  111. Schulman S. Hypercoagulability preceding cancer (Are anticoagulants also antineoplastic?). J Thromb Haemost. 2005;3:581–583
  112. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833–1840
  113. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 2005;92:1212–1220
  114. Bergqvist D, Solhaug J-H, Holmdahl L, Eriksson U, Andersson M, Boberg B, et al. Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran, A multicentre study on thromboprophylaxis in elective abdominal surgery. Clin Drug Invest. 2004;24:127–136
  115. Lee WM, Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005;28:351–370
  116. Anonymous Is that it, then, for blockbuster drugs?. Lancet. 2004;9440:1100;Sept. 25-Oct 1
  117. Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg (Is there a “high risk” group?). Am J Surg. 1970;120:527–530
  118. Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecological surgery using labelled fibrinogen-phlebography and lung scanning. J Obstet Gynaecol Br Commonw. 1974;81:311–316
  119. Rosenberg IL, Evans M, Pollock AV. Prophylaxis of postoperative leg vein thrombosis by low dose subcutaneous heparin or peroperative calf muscle stimulation: a controlled clinical trial. BMJ. 1975;1:649–651
  120. Allan A, Williams JT, Bolton JP, Le Quesne LP. The use of graduated compression stockings in the prevention of postoperative deep vein thrombosis. Br J Surg. 1983;70:172–174
  121. Sue-Ling HM, Johnston D, McMahon MJ, Philips PR, Davies JA. Pre-operative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet. 1986;1:1173–1176
  122. Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L, et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest. 1988;18:561–567
  123. Ho YH, Seow-Choen F, Leong A, Eu KW, Nyam D, Teoh MK. Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients. Dis Colon Rectum. 1999;42:196–202discussion 202-3
  124. Baykal C, Al A, Demirtas E, Ayhan A. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. Eur J Gynaecol Oncol. 2001;22:127–130
  125. Boncinelli S, Marsili M, Lorenzi P, Fabbri LP, Pittino S, Filoni M, et al. Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin. Minerva Anestesiol. 2001;67:693–703
  126. McLeod RS, Geerts WH, Sniderman KW, Greenwood C, Gregoire RC, Taylor BM, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian Colorectal DVT Prophylaxis Trial: a randomized, double-blind trial. Ann Surg. 2001;233:438–444
  127. Kirwan CC, Nath E, Byrne GJ, McCollum CN. Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey. BMJ. 2003;327:597–598
  128. Levine MN. Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treat Rev. 2002;28:145–149
  129. Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist. 2005;10:72–79
  130. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–3488
  131. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved International Normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078–3083
  132. Lee A. Treatment of venous thromboembolism in cancer patients. Cancer Control. 2005;12:17–21
  133. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol. 2005;16:696–701
  134. Lee AYY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol. 2004;128:291–302
  135. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):401S–428S
  136. Petralia G, Kakkar AK. Antithrombotic therapy with low molecular weight heparin in cancer patients. Eur J Med Res. 2004;9:119–124
  137. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000;160:181–188
  138. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis (A meta-analysis of randomized, controlled trials). Ann Intern Med. 1999;130:800–809
  139. Ageno W, Steidl L, Marchesi C, Dentali F, Mera V, Squizzato A, et al. Selecting patients for home treatment of deep vein thrombosis: the problem of cancer. Haematologica. 2002;87:286–291
  140. O’Shaughnessy D, Miles J, Wimperis J. UK patients with deep-vein thrombosis can be safely treated as out-patients. QJM. 2000;93:663–667
  141. Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med. 1998;158:1809–1812
  142. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. The Tasman Study Group Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682–687
  143. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677–681
  144. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337:657–662
  145. Van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004;4:CD001100
  146. Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001;134:191–202
  147. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety (Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis). N Engl J Med. 2001;344:626–631
  148. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, et al. Prevention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998;338:409–414
  149. Rutherford RB. Prophylactic indications for vena cava filters: critical appraisal. Semin Vasc Surg. 2005;18:158–165
  150. Deitcher SR, Kessler CM, Merli G, Rigas J, Lyons RM, Cort S. Secondary prevention of venous thromboembolic events (VTE) in patents with active malignancy: a randomized study of enoxaparin sodium alone vs. initial enoxaparin sodium followed by warfarin for a 180-day period. [abstract] J Thromb Haemost. 2003;1(Suppl 1):OC194
  151. LITE InvestigatorsHull RD, Pineo GF, Mah AF, Brant RF. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. [abstract] J Thromb Haemost. 2003;1(Suppl 1):1373a
  152. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729–1735
  153. Noble SI, Nelson A, Turner C, Finlay IG. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ. 2006;332:577–580
  154. Sack GH, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine. 1977;56:1–37
  155. Weick JK. Intravascular coagulation in cancer. Semin Oncol. 1978;5:203–211
  156. Goodnight SH. Bleeding and intravascular clotting in malignancy: a review. Ann NY Acad Sci. 1974;230:271–288
  157. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25:173–182
  158. Falanga A, Donati MB. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol. 2001;73:137–144
  159. Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res. 2001;102:V187–V194
  160. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003;72:43–52
  161. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001;V215–V224
  162. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost. 1999;25:137–145
  163. Lee AY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res. 2003;110:167–172
  164. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W. The thrombogenic effect of cancer drug chemotherapy in women with stage II breast cancer. N Engl J Med. 1988;318:404–407
  165. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who receive adjuvant therapy for breast cancer. J Clin Oncol. 1991;9:286–294
  166. Pritchard KI, Paterson AHG, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol. 1996;14:2731–2737
  167. Rance A, Emmerich J, Guedj C, Fiessinger J-N. Occult cancer in patients with bilateral deep-vein thrombosis. Lancet. 1997;350:1448–1449
  168. Lin J, Proctor MC, Varma M, Greenfield LJ, Upchurch GR, Henke PK. Factors associated with recurrent venous thromboembolism in patients with malignant disease. J Vasc Surg. 2003;37:976–983
  169. Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Hemost. 1997;78:141–144
  170. Goldhaber SZ, Tapson VF DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93:259–262
  171. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost. 1999;25:147–155
  172. Lin J, Wakefield TW, Henke P. Risk factors associated with venous thromboembolic events in patients with malignancy. Blood Coag Fibrinol. 2006;17:265–270
  173. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism is hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24:484–490
  174. Edwards RL, Silver J, Rickles FR. Human tumor procoagulants: registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemost. 1993;69:205–213
  175. Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol. 1998;152:399–411
  176. Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol. 2003;11:673–678
  177. DeCicco M. The prothrombotic state in cancer: pathogenic mechanisms. Clin Rev Oncol Hematol. 2004;50:187–196
  178. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867
  179. Geng JG. Interaction of vascular endothelial cells with leukocytes, platelets and cancer cells in inflammation, thrombosis and cancer growth and metastasis. Acta Pharmacol Sin. 2003;24:1297–1300
  180. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 1991;65:859–873
  181. Gilbert GE, Sims PJ, Wiedmer T, Furie B, Furie BC, Shattil SJ. Platelet-derived MP express high affinity receptors for factor VIII. J Biol Chem. 1991;266:17261–17268
  182. Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol. 1998;161:4382–4387
  183. Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood. 2002;99:3962–3970
  184. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res. 2003;59:277–287
  185. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197:1585–1598
  186. Martinez MC, Tesse A, Zobairi F, Andriantsitohaina R. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol. 2005;288:H1004–H1009
  187. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol. 1967;13:269–288
  188. Morel O, Toti F, Hugel B, Freyssinet JM. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol. 2004;11:156–164
  189. Ahn YS. Cell-derived microparticles: “Miniature envoys with many faces.”. J Thromb Haemost. 2005;3:884–887
  190. Welterman A, Hron G, Kollars M, Kornek G, Quehenberger P, Eichenger S, et al. The association between tissue-factor exposing microparticles and the activation of the coagulation system in cancer patients. Blood. 2004;104:2589
  191. Del Conde ID, Bahrwani L, Pendurthi U, Thiagrajan P, Lopez J. Extremely high levels of microvesicle-associated tissue factor in patients with cancer-related thrombosis. Blood. 2004;104:2605
  192. Jy W, Jimenez JJ, Cheng P, Mauro LM, Horstman LL, Ahn ER, et al. Endothelial derived microparticles (EMP) bind and complex with unusually-large multimers of von Willebrand factor (ULvWF) and act as potent inducers of platelet adhesion and aggregation. Blood. 2004;104:3376
  193. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology (Bethesda). 2005;20:22–27
  194. Chirinos JA, Zambrano JP, Virani SS, Jimenez JJ, Jy W, Ahn E, et al. Correlation between apoptotic endothelial microparticles and serum interleukin-6 and C-reactive protein in healthy men. Am J Cardiol. 2005;95:1258–1260
  195. Chirinos JA, Heresi GA, Velasquez H, Jy W, Jimenez JJ, Ahn E, et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol. 2005;45:1467–1471
  196. Kushak RI, Nestoridi E, Lambert J, Selig MK, Ingelfinger JR, Grabowski EF. Detached endothelial cells and microparticles as sources of tissue factor activity. Thromb Res. 2005;116:409–419
  197. Furie B, Furie BC. Cancer-associated thrombosis. Blood Cells Mol Dis. 2006;36:177–181
  198. Dvorak HF, Quay SC, Orenstein NS, Dvorak AM, Hahn P, Bitzer AM, et al. Tumor shedding and coagulation. Science. 1981;212:923–924
  199. Dvorak HF, Van DeWater L, Bitzer AM, Dvorak AM, Anderson D, Harvey VS, et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res. 1983;43:4434–4442
  200. Van DeWater L, Tracy PB, Aronson D, Mann KG, Dvorak HF. Tumor generation of thrombin via functional prothrombinase assembly. Cancer Res. 1985;45:5521–5525
  201. Yu JL, May L, Lhotak V, Shahrzad , Shirasawa S, Weltz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2004;105:1734–1741
  202. Zwicker JI, Furie BC, Kos C, La Rocca T, Bauer KA, Furie B. Trousseau’s syndrome revisited (Tissue factor-bearing microparticles in pancreatic cancer). Blood. 2005;106:259A
  203. Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanoporn P, Schaub RG. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003;38:1075–1089
  204. Rectenwald JE, Myers DD, Hawley AE, Longo C, Henke PK, Guire KE, et al. D-Dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis (A pilot study). Thromb Haemost. 2005;94:1312–1317
  205. Johnston GI, Cook RG, McEver RP. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell. 1989;56:1033–1044
  206. Frenette PS, Moyna C, Hartwell DW, Lowe JB, Hynes RO, Wagner DD. Platelet-endothelial interactions in inflamed mesenteric venules. Blood. 1998;91:1318–1324
  207. Dunlop LC, Skinner MP, Bendall LJ, Favaloro EJ, Castaldi PA, Gorman JJ, et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med. 1992;175:1147–1150
  208. Lorenzon P, Vecile E, Nardon E, Ferrero E, Harlan JM, Tedesco F, et al. Endothelial cell E- and P-selectin and vascular cell adhesion molecule-1 function as signaling receptors. J Cell Biol. 1998;142:1381–1391
  209. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J. 2003;24:2166–2179
  210. Chen M, Geng JG. P-Selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz). 2006;54:75–84
  211. Woollard KJ. Soluble bio-markers in vascular disease: much more than gauges of disease?. Clin Exp Pharmacol Physiol. 2005;32:233–240
  212. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest. 1997;100:2085–2093
  213. Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med. 2000;191:1413–1422
  214. Kameda H, Morita I, Handa M, Kaburaki J, Yoshida T, Mimori T, et al. Re-expression of functional P-selectin molecules on the endothelial cell surface by repeated stimulation with thrombin. Br J Haematol. 1997;97:348–355
  215. Khew-Goodall Y, Butcher CM, Litwin MS, Newlands S, Korpelainen EI, Noack LM, et al. Chronic expression of P-selectin on endothelial cells stimulated by the T-cell cytokine, interleukin-3. Blood. 1996;87:1432–1438
  216. Gotsch U, Jager U, Dominis M, Vestweber D. Expression of P-selectin on endothelial cells is upregulated by LPS and TNF-alpha in vivo. Cell Adhes Commun. 1994;2:7–14
  217. Weller A, Isenmann S, Vestweber D. Cloning of the mouse endothelial selectins (Expression of both E- and P-selectin is inducible by tumor necrosis factor alpha). J Biol Chem. 1992;267:15176–15183
  218. Semenov AV, Romanov YA, Loktionova SA, Tikhomirov OY, Khachikian MV, Vasil’ev SA, et al. Production of soluble P-selectin by platelets and endothelial cells. Biochemistry (Moscow). 1999;64:1326–1335
  219. Matzdorff AC, Kuhnel G, Kemkes-Matthes B, Voss R. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer. J Thromb Thrombolysis. 2001;12:129–139
  220. Armstead VE, Minchenko AG, Schuhl RA, Hayward R, Nossuli TO, Lefer AM. Regulation of P-selectin expression in human endothelial cells by nitric oxide. Am J Physiol. 1997;273:H740–H746
  221. Minamino T, Kitakaze M, Kuzuya T, Hori M. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. J Cardiol. 1999;33:103–104
  222. Spertini O, Cordey AS, Monai N, Giuffre L, Schapira M. P-Selectin glycoprotein ligand 1 is a ligand for L-selectin on neutrophils, monocytes, and CD34+ hematopoietic progenitor cells. J Cell Biol. 1996;135:523–531
  223. Symon FA, Lawrence MB, Williamson ML, Walsh GM, Watson SR, Wardlaw AJ. Functional and structural characterization of the eosinophil P-selectin ligand. J Immunol. 1996;157:1711–1719
  224. Hrachovinova I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med. 2003;9:1020–1025
  225. Wakefield TW, Strieter RM, Downing LJ, Kadell AM, Wilke CA, Burdick MD, et al. P-Selectin and TNF inhibition reduce venous thrombosis inflammation. J Surg Res. 1996;64:26–31
  226. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjaman C, Hsu YM, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 1992;359:848–851
  227. Myers D, Farris D, Hawley A, Wrobleski S, Chapman A, Stoolman L, et al. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. J Surg Res. 2002;108:212–221
  228. Sullivan VV, Hawley AE, Farris DM, Knipp BS, Varga AJ, Wrobleski SK, et al. Decrease in fibrin content of venous thrombi in selectin-deficient mice. J Surg Res. 2003;109:1–7
  229. Downing LJ, Wakefield TW, Strieter RM, Prince MR, Londy FJ, Fowlkes JB, et al. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J Vasc Surg. 1997;25:816–827
  230. Wakefield TW, Strieter RM, Schaub R, Myers DD, Prince MR, Wrobleski SK, et al. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy. J Vasc Surg. 2000;31:309–324
  231. Myers DD, Henke PK, Bedard PW, Wrobleski SK, Kalia N, Shaw G, et al. Treatment with an oral small molecule inhibitor of P-selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg. 2006;44:625–632
  232. Norman KE, Moore KL, McEver RP, Ley K. Leukocyte rolling in vivo is mediated by P-selectin glycoprotein ligand-1. Blood. 1995;86:4417–4421
  233. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA. 1995;92:7450–7454
  234. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA. 2000;97:13835–13840
  235. Siddiqui FA, Desai H, Amirkhosravi A, Amaya M, Francis JL. The presence and release of tissue factor from human platelets. Platelets. 2002;13:247–253
  236. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor; another view of thrombosis. Proc Natl Acad Sci USA. 1999;96:2311–2315
  237. Jy W, Horstman LL, Wang F, Duncan RC, Ahn YS. Platelet factor 3 in plasma fractions: its relation to microparticle size and thromboses. Thromb Res. 1995;80:471–482
  238. Ludwig RJ, Alban S, Bistrian R, Boehncke W-H, Kaufmann R, Henschler R, et al. The ability of different forms of heparin to suppress P-selectin function in vitro correlates to their inhibitory capacity on blood-borne metastasis in vivo. Thromb Haemost. 2006;95:535–540
  239. Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanoporn P, Schaub RG. P-Selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003;38:1075–1089
  240. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197:1585–1598
  241. Edwards RL, Rickles FR, Bobrove AM. Mononuclear cell tissue factor: cell of origin and requirements for activation. Blood. 1979;54:359–370
  242. Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in people with cancer (Mononuclear cell tissue factor generation). J Lab Clin Med. 1981;98:917–928
  243. Fernandez PM, Rickles FR. Tissue factor and angiogenesis in cancer. Curr Opin Hematol. 2002;9:401–406
  244. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA. 1995;92:8205–8209
  245. Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest. 1998;101:1372–1378
  246. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature. 2000;407:258–264
  247. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Hemost. 2003;1:1495–1503
  248. Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W. A role of tissue factor in cell adhesion and migration mediated by interaction with actin binding protein. J Cell Biol. 1998;140:1241–1253
  249. Muller M, Albrecht S, Golfert F, Hofer A, Funk RHW, Magdolen V, et al. Localization of tissue factor in actin filament-rich membrane areas of epithelial cells. Exp Cell Res. 1999;248:136–147
  250. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA. 1992;89:11832–11836
  251. Fischer EG, Riewald M, Huang HY, Miyagi Y, Kubota Y, Mueller BM, et al. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest. 1999;104:1213–1221
  252. Karpatkin S. Does hypercoagulability awaken dormant tumor cells in the host?. J Thromb Hemost. 2004;2:2103–2106
  253. Kamath L, Meydani A, Foss F, Kuliopulos A. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res. 2001;61:5933–5940
  254. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol. 2005;25:1545–1550
  255. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem. 2000;275:1521–1524
  256. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994;94:1320–1327
  257. Abe K, Shoji M, Chen J, Bierhaus A, Danve I, Micko C, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA. 1999;96:8663–8668
  258. Kakkar AK, De Ruvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet. 1995;346:1004–1005
  259. Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J. 2003;17:476–478
  260. Giesen PL, Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost. 2000;26:379–384
  261. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor coagulation triad. J Thromb Hemost. 2005;3:1590–1596
  262. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003;39:184–191
  263. Falanga A. Biological and clinical aspects of anticancer effects of antithrombotics. Pathophys Haemost Thromb. 2003;33:389–392
  264. Prandoni P. Prevention and treatment of deep vein thrombosis in cancer patients. Vessels. 1996;2:31–34
  265. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med. 1996;100:269–277
  266. Lee AY. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treatment Rev. 2002;28:137–140

PII: S0011-3840(07)00015-9

doi: 10.1067/j.cpsurg.2007.01.004

Current Problems in Surgery
Volume 44, Issue 3 , Pages 157-216 , March 2007

Article Tools

* Image Usage & Resolution